Oxymetazoline: reduction of subconjunctival hemorrhage incidence after intravitreal injections.

Objective: Subconjunctival hemorrhage (SCH) is an important minor side effect that might affect patient compliance to antivascular endothelial growth factor (anti-VEGF) intravitreal injection treatment (IVI). We sought to compare SCH incidence and pain score responses after topical oxymetazoline in naïve patients undergoing a single IVI of ranibizumab for diabetic macular edema.

Methods: Prospective, randomized, double-blinded, single centre study.